Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
R-Pharm
Boehringer Ingelheim
M.D. Anderson Cancer Center
Pfizer
M.D. Anderson Cancer Center
University of Wisconsin, Madison
Groupe Oncologie Radiotherapie Tete et Cou
Washington University School of Medicine
University of California, San Diego
University of California, San Diego
University College, London